Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Teleflex Gets FDA 510(k) Clearance To Market Pressure Injectable ARROW PICC

RELATED NEWS
Trade TFX now with 

Teleflex Incorporated (TFX: Quote), a global provider of medical devices for critical care and surgery, announced it has received FDA 510(k) clearance to market its pressure injectable ARROW PICC preloaded with the ARROW VPS Vascular Positioning System Stylet. The ARROW VPS replaces the need for confirmatory chest X-ray in the presence of a stable Blue Bullseye by using real-time intravascular Doppler, ECG and advanced algorithmic logic to notify the clinician that the catheter tip has reached the optimal location. The preloaded option improves clinician ease of use for vascular navigation and catheter tip positioning.

From a workflow perspective, the preloaded ARROW PICC benefits clinicians by saving the time and process of loading the ARROW VPS Stylet into the catheter. Clinically, the ARROW VPS confirms accurate catheter tip position in the lower 1/3 of the SVC-Cavo-Atrial Junction, which has been proven to reduce complications such as thrombosis.

Click here to receive FREE breaking news email alerts for Teleflex Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.